Molecular structure of L-365,260, CAS Number: 118101-09-0
L-365,260 (CAS 118101-09-0)
See product citations (1)
Alternate Names:
N-[(3R)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-N′-(3-methylphenyl)-urea
Application:
L-365,260 is a non-peptide competitive CCK-BR antagonist
CAS Number:
118101-09-0
Purity:
≥99%
Molecular Weight:
398.46
Molecular Formula:
C24H22N4O2
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Available in US only.
Available in US only.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
L-365,260 is a non-peptide competitive CCK-BR (CCK2; CCK-B; cholecystokinin 2) receptor antagonist reported to inhibit the cyclic AMP-dependent protein kinase pathway. CCK is a neuroendocrine peptide described to play an important role in cell growth, cell proliferation, and other biological functions. Lung cancer cell studies show that L-365,260 blocks the elevated levels of cytosolic Ca2+ induced by CCK-8, and inhibits CCK-8 binding to SCLC cells and the cell proliferation of NCI-H209 cells. Other CCKB inhibitors include CI 988 (sc-205244).
L-365,260 (CAS 118101-09-0) References
- Influence of L-365,260, a CCK-B/gastrin receptor antagonist, on tetragastrin-stimulated mucin metabolism in rat gastric mucosa. | Komuro, Y., et al. 1999. Pharmacology. 59: 11-20. PMID: 10352422
- L-365,260 inhibits in vitro acid secretion by interacting with a PKA pathway. | Oiry, C., et al. 1999. Br J Pharmacol. 127: 259-67. PMID: 10369481
- Nonpeptide cholecystokinin-2 receptor agonists. | Kalindjian, SB., et al. 2001. J Med Chem. 44: 1125-33. PMID: 11312913
- CI-988 inhibits growth of small cell lung cancer cells. | Moody, TW. and Jensen, RT. 2001. J Pharmacol Exp Ther. 299: 1154-60. PMID: 11714907
- L-365,260 reversed effect of sincalide against morphine on electrical and mechanical activities of rat duodenum in vitro. | Yang, CX., et al. 2002. Acta Pharmacol Sin. 23: 582-6. PMID: 12100748
- A randomised, double blind, placebo controlled crossover study of the cholecystokinin 2 antagonist L-365,260 as an adjunct to strong opioids in chronic human neuropathic pain. | McCleane, GJ. 2003. Neurosci Lett. 338: 151-4. PMID: 12566175
- Devazepide, a nonpeptide antagonist of CCK receptors, induces apoptosis and inhibits Ewing tumor growth. | Carrillo, J., et al. 2009. Anticancer Drugs. 20: 527-33. PMID: 19407653
- Cholecystokinin action on layer 6b neurons in somatosensory cortex. | Chung, L., et al. 2009. Brain Res. 1282: 10-9. PMID: 19497313
- A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. | Lotti, VJ. and Chang, RS. 1989. Eur J Pharmacol. 162: 273-80. PMID: 2721567
- The CCKB receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice. | Hernando, F., et al. 1994. Eur J Pharmacol. 261: 257-63. PMID: 7813546
- Analysis of variation in L-365,260 competition curves in radioligand binding assays. | Harper, EA., et al. 1996. Br J Pharmacol. 118: 1717-26. PMID: 8842437
Inhibitor of:
CCK-BR.Activator of:
CCK-BR.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
L-365,260, 10 mg | sc-311370 | 10 mg | $161.00 | |||
| US: Only available in the US | ||||||
L-365,260, 50 mg | sc-311370A | 50 mg | $906.00 | |||
| US: Only available in the US | ||||||